(Q44143356)

30 November 2017

0 references

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials (English)

1 reference

30 November 2017

1 reference

1 reference

2

B Ahrén

1 reference

30 November 2017

M Monami

1

1 reference

30 November 2017

I Dicembrini

series ordinal

3

1 reference

30 November 2017

E Mannucci

series ordinal

4

1 reference

30 November 2017

publication date

20 September 2012

1 reference

Diabetes, Obesity and Metabolism

30 November 2017

published in

1 reference

30 November 2017

volume

15

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

112-120

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

30 November 2017

cites work

1 reference

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

21 January 2018

1 reference

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines

21 January 2018

1 reference

DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease

21 January 2018

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

21 January 2018

1 reference

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

21 January 2018

1 reference

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12000

1 reference

30 November 2017

1 reference